Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk.

Jordan H CreedAnders E BerglundRobert J RounbehlerShivanshu AwasthiJohn L ClevelandJong Y Park Kosj YamoahTravis A Gerke

Published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2019)

Differences in gene expression by race for three commercial panels for prostate cancer prognosis indicate that further study of their effectiveness in AAM with long-term follow-up is warranted.

Keyphrases

prostate cancer
gene expression
radical prostatectomy
dna methylation
randomized controlled trial
systematic review